Formation of the Bcr-Abl chimeric protein is the molecular hallmark of Philadelphia-positive leukemia. Normal Bcr is a complex protein which has been found in the cytoplasm, has serine kinase activity, and has been implicated in cellular signal transduction. However, we have recently demonstrated that Bcr can also associate with condensed chromatin. Since two major Bcr proteins have been characterized (p160 Bcr and p130 Bcr ), we sought to determine if different forms of Bcr localized to the nucleus vs the cytoplasm. Metabolic labeling and Western blotting experiments were performed using nuclear and cytoplasmic extracts of three human Philadelphia-negative leukemia/lymphoma cell lines (KG-1, HL-60, and Jurkat). Both methodologies showed that p160
Introduction
Bcr is a multi-functional protein with a critical role in leukemias bearing the Philadelphia (Ph) translocation. In chronic myelogenous leukemia (CML), as well as in a small percentage of Philadelphia-positive acute leukemias, the reciprocal translocation between chromosomes 9 and 22 1,2 juxtaposes the Abelson (ABL) gene and the breakpoint cluster region (BCR) gene. [3] [4] [5] [6] Both the BCR-ABL and the ABL-BCR genes are transcribed into mRNAs. However, to date, only BCR-ABL has been found to be translated to proteins. [7] [8] [9] [10] Three major functional domains have been identified for normal Bcr: (1) a serine/threonine kinase region in its amino terminus; (2) a CDC24 homologous GTP exchange factor (GEF) domain within its central region; and (3) a GTPase-activating protein (GAP) domain in its carboxyl terminus. [11] [12] [13] [14] [15] [16] Because intracellular signaling mechanisms are mediated via phosphorylation and/or GTP-binding proteins respectively, a role for Bcr in signal transduction pathways has been inferred. Consistent with such a role, early studies, both by our group and by others, localized Bcr to the cytoplasm using light microscopy and immunohistochemistry techniques. 17, 18 More recently, however, our group demonstrated that Bcr associates with condensed chromatin. 19 Although a functional role for nuclear Bcr has not yet been demonstrated, Bcr can phosphorylate histones in vitro. 13 Furthermore, proteins with serine kinase activity which attach to condensed chromatin are generally active in cell cycle regulation.
Two major Bcr proteins (130 kDa and 160 kDa proteins) have been characterized in detail, 12, 17, 20, 21 though other putative Bcr-related proteins of various sizes have also been described. 24 In the current study, we sought to determine if the distinct forms of the Bcr protein preferentially localize to different cellular compartments. We used immunoprecipitates of nuclear and cytoplasmic extracts of metabolically labeled human leukemia and lymphoma lines KG-1, HL-60 and Jurkat, as well as immunoblotting of unlabeled immunoprecipitates. Our current results verify that both the 160 kDa and 130 kDa Bcr proteins are found in the cytoplasm. However, these proteins are also associated with metaphase chromatin, as well as condensed interphase chromatin. In the nucleus, both p160
Bcr and p130 Bcr are discerned, though the 130 kDa protein is the preponderant form, especially in KG-1 and HL-60 cells.
Materials and methods

Cell lines
We used the human acute myelogenous leukemia cell line KG-1, the human T cell lymphoma cell line Jurkat, and the human myelocytic leukemia cell line HL-60 (American Type Culture Collection, Rockville, MD, USA). These cell lines are Ph-negative and do not contain the Bcr-Abl protein. All cells were cultured in RPMI-1640 (BioWhittaker, Walkersville, MD, USA) containing 10% inactivated fetal calf serum (Sigma, St Louis, MO, USA) in a 5% CO 2 incubator at 37°C.
Antisera
For detection of the Bcr protein, we used mouse monoclonal antibody Bcr7C6 (Oncogene Science, Manhasset, NY, USA) raised against the synthetic peptide bcr686 (SSINEGITPRQS) of Bcr. 17 For control experiments to verify the purity of our cytoplasmic extracts, we used mouse monoclonal anti-focal adhesion kinase (anti-Fak) antibody (Transduction Laboratories, Lexington, KY, USA). Similarly, to verify the purity of our nuclear extracts, we used the mouse monoclonal antiNuMa antibody (Oncogene) which detects the nuclear matrix protein (NuMa). Isotypic controls included mouse monoclonal anti-laminin (IgG 2 A control for the anti-Bcr sera) and anti-thyroglobulin serum (IgG 1 control for the anti-Fak sera) (DAKO, Carpinteria, CA, USA).
Immunoelectron microscopy
Cells were fixed in either 2% glutaraldehyde (Sigma) or in 4% paraformaldehyde/0.1% glutaraldehyde in 0.1 M phosphate buffer (pH 7.3) for 1 h at 4°C. After a rinse in the same buffer, cells were dehydrated through a series of graded solutions of dimethylformamide (Sigma) (50, 75 , and 90%, vol/vol) in water at 0°C. Cells were then infiltrated through a series of graded solutions of Lowicryl K4M/dimethylformamide (Polysciences, Warrington, PA, USA), 1:2, 1:1, and 2:1 (vol/vol), at 0°C and then incubated overnight in 100% Lowicryl K4M at −20°C. Polymerization at −20°C was brought about by indirect overnight ultraviolet irradiation. The blocks were irradiated for another 2-to 3-day period at room temperature to improve the sectioning properties. Thin sections (900 A) were cut with a diamond knife on a Reichert (Warrington, PA, USA) Ultracut E microtome and mounted on Formvar nickel grids (Polysciences).
Immunolabeling for electron microscopy
Thin sections were floated on Tris-buffered saline (TBS) for 5 min. (In some cases, this was followed by exposure to TBS/0.5% ammonium chloride for 10 min to block free aldehyde groups.) After additional preincubation in TBS/0.1% bovine serum albumin/10% (vol/vol) normal goat serum for 15 min, the grids were kept overnight with the primary antibody (7C6 anti-Bcr serum or isotypic control antibody) in a wet chamber at 4°C. The grids were then washed vigorously with TBS and labeled with AuroProbe (EM GAM IgG; Amersham, Arlington Heights, IL, USA) for 30 min. Finally, the grids were washed vigorously with water, dried, and examined under the electron microscope (JOEL 1200) at 40 KeV.
S-methionine metabolic labeling
4 × 10 7 cells (per sample) were metabolically labeled with 300 Ci 35 S-methionine (Amersham) in 3-ml methionine-free medium containing 5% dialyzed fetal calf serum. Cells were incubated at 37°C in 5% CO 2 incubator for 4.5 h. For whole cell extracts, the cells were then lysed in 1 ml of lysis buffer containing 50 mM Tris.Cl (pH 8.0), 150 mM NaCl, 100 g/ml PMSF (phenylmethylsulfonyl fluoride), 1 g/ml aprotinin, 1% NP-40. Alternatively, cytoplasmic and nuclear extracts were prepared (see below). Lysates were precleared by incubating with 1 g total mouse IgG serum. One microgram of antibody was added to the precleared lysate and incubated at 4°C for an hour. Protein-A or G agarose beads were added for an additional hour. The protein/antibody complex was obtained by centrifugation and samples were run on an SDS-Page and autoradiographed.
Nuclear and cytoplasmic extracts
Cytoplasmic and nuclear extracts of labeled cells were separated as previously described by Dignam et al. 23 Briefly, cells were lysed in 1 ml of solution containing 10 mM HEPES, 1.5 mM MgCl 2 , 10 mM KCl, 0.2 mM PMSF, and 0.5 mM DTT (dithiothreitol). Cells were centrifuged for 15 min at 3300 g and the supernatant containing the cytoplasmic extract was retained. The nuclear pellet was resuspended in half volume of buffer containing 20 mM HEPES (4(-2-hydroxyethyl)-1-piperazeethanesulfonic acid)), 25% glycerol, 1.5 mM MgCl 2 , 0.02 M KCl, 0.2 mM EDTA (ethylenediaminetetraacetic acid), 0.2 mM PMSF, and 0.5 mM DTT. An equal volume of a second buffer containing 20 mM HEPES, 25% glycerol, 1.5 mM MgCl 2 , 500 mM NaCl, 0.2 mM EDTA, 0.2 mM PMSF, and 0.5 mM DTT was added. The solution was rocked 30 min at 4°C and then microfuged for 30 min. The supernatant was retained for immunoprecipitation.
Alternatively, cytoplasmic and nuclear extracts of unlabeled cells were separated by a method described by Abmayr et Leukemia al. 24 Briefly, cells were lysed for 5 min on ice in 2 ml of buffer containing 50 mM Tris.Cl pH 8.0, 100 mM NaCl, 5 mM MgCl 2 , 0.5% NP-40, followed by centrifuging cells at 500 g for 5 min. The supernatant containing the cytoplasmic extract was removed, and the nuclear pellet was resuspended in 2 ml of the same buffer and nuclear extract was recovered by centrifuging at 500 g for 5 min. Proteins were extracted for 20 min in 50 mM Tris.Cl (pH 8.0), 150 mM NaCl, 0.1% SDS, 100 g/ml PMSF, 1 g/ml aprotinin, 1% NP-40, 0.5% sodium deoxycholate.
Immunoprecipitation and immunoblotting
Immunoprecipitation was performed by adding 2 g of antibody to 1 ml of lysates of whole cell, nuclear, and cytoplasmic extracts and incubating at 4°C for an hour. Protein A/G agarose beads were added for an additional hour. The protein/antibody complex was obtained by centrifugation (14 000 r.p.m., 20 s) and samples were run on a 6% SDS gel. 
Results
Immunoelectron microscopy
HL-60 cells in G0/G1 were exposed to gold-labeled anti-Bcr serum. Assessment of these cells using electron microscopy showed the presence of Bcr in the nucleus (Figure 1a) . 19 Immunolabeling was limited primarily to the heterochromatin, which included peripheral and perinucleolar heterochromatin, as well as the heterochromatin dispersed throughout the nucleus. Cells exposed to gold-labeled isotypic antibody showed no labeling (Figure 1b) . Results in interphase KG-1 cells also demonstrated the association between Bcr and heterochromatin (data not shown).
KG-1 cells undergoing mitosis were also exposed to the gold-labeled anti-Bcr serum. Electron microscopy analysis showed that the mitotic chromosome was labeled with the antibody (Figure 2a) . In contrast, cells exposed to the isotypic antibody showed no labeling (Figure 2b) . Similar results were seen in mitotic HL-60 cells (data not shown).
Metabolic labeling
KG-1, HL-60 and Jurkat cells were labeled with 35 S-methionine, and whole cell, nuclear and cytoplasmic extracts were obtained. Metabolic labeling followed by immunoprecipitation with anti-Bcr sera showed 160 and 130 kDa Bcr proteins in whole cell extracts and in cytoplasmic extracts (Figure 3) . Nuclear extracts also contained Bcr protein, albeit predominantly the 130 kDa form (Figure 3) . The 130 and 160 kDa Bcr proteins were not seen in lanes in which immunoprecipitation was performed with isotypic antibody or in the presence of Bcr cognate peptide block (Figure 3a and c) .
Immunoblotting
Immunoprecipitation with anti-Bcr followed by Western blotting with anti-Bcr sera also showed 160 and 130 kDa Bcr proteins in KG-1 whole cell and cytoplasmic extracts (Figure 4) . Similar to the metabolic labeling experiments, the nuclear extracts showed p130 Bcr . To demonstrate that the nuclear extracts were not contaminated with cytoplasmic material, we also performed immunoprecipitation with anti-Fak followed by Western blotting with anti-Fak sera. (Fak is a focal adhesion kinase which is localized to the cytoplasm. 25 ) Fak was seen in the whole cell and cytoplasmic extracts, but not in the nuclear extracts ( Figure 5 ). Western blotting with the anti-NuMa sera demonstrated that cytoplasmic extracts were free of contamination by nuclear material (Figure 6 ).
Discussion
The best-studied role for BCR is as a cytoplasmic signaling protein. 17, 18 Indeed, Bcr has been shown to have activities associated with the major intracellular signal transduction pathways-serine kinase activity, as well as the ability to regulate G-proteins through its GTP exchange factor (GEF) and GTPase-activating protein (GAP) domains. [11] [12] [13] [14] [15] [16] 26 Our current results verify that the two well-established forms of the Bcr protein, p160
Bcr and p130
Bcr , are both found in the cytoplasm. However, p130
Bcr as well as small amounts of p160
Bcr are also detected in nuclear extracts (Figures 3 and  4) . The latter results are consistent with our finding that Bcr associates with condensed chromatin in the form of mitotic chromosomes (mitotic cells) or heterochromatin (interphase cells) (Figures 1 and 2) . 19 Condensation of chromatin is required for progression through the cell cycle and is the prelude to mitosis. Furthermore, serine kinases which interact with condensed chromatin often serve as cell cycle regulatory proteins. Other studies also hint at a possible role for Bcr in processes other than signal transduction. For instance, Bcr forms a complex in vivo with 14-3-3 proteins, 27, 28 and these proteins are substrates for the Bcr serine/threonine kinase. 27 14-3-3 proteins are both nuclear 29 and cytoplasmic. 30 They have a variety of functions including cell cycle and DNA dam-
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Western age checkpoint control, 31, 32 and nuclear export of the Cdc25C mitotic inducer, 33 in addition to their interaction with Raf in the mitogen activated protein kinase cascade. [34] [35] [36] Bcr has also been demonstrated to bind the normal Abl protein (through SH2 domains), and these two molecules can regulate each other. [37] [38] [39] [40] Interestingly, Abl is known to be both cytoplasmic 18 and nuclear, 41 and has been demonstrated to interact directly with meiotic chromosomes. 42 Furthermore, nuclear Abl is differentially phosphorylated during cell cycle, a process mediated at least in part by Cdc2. 43 As a serine kinase, Bcr can also phosphorylate the Cdc2 substrate histone in vitro 13 and can inhibit the tyrosine kinase activity of Abl as well. 39 Taken together, these findings suggest that a role for Bcr in cell cycle control merits investigation.
Of further interest in regard to the nuclear role of Bcr are the recent reports demonstrating that both Bcr and Bcr-Abl bind through the Bcr CDC24 homology domain, to the DNA repair xeroderma pigmentosum group B (XPB) protein. 44, 45 Xeroderma pigmentosum is an inherited DNA repair disorder characterized by serious sequelae of ultraviolet light-induced DNA damage. XPB is a component of the transcription factor IIH (TFIIH) core complex (reviewed in Ref. 46) . TFIIH plays a role in initiation of transcription, as well as in DNA repair, and has also been linked to the cell cycle through its cdk7/cyclin H kinase subcomplex (reviewed in Ref. 46 ). These observations suggest that the effects of Bcr-Abl vs Bcr on XPBrelated DNA repair should be investigated in CML, especially since one of the hallmarks of this disease is genomic instability manifested by clonal evolution that inevitably leads to blast crisis (and hence death).
In summary, we demonstrate that Bcr has nuclear, as well as cytoplasmic localization. It therefore appears that Bcr is an extremely complex protein. Its cytoplasmic role has been extensively studied and it is now known that Bcr acts on signal transduction through both kinase and G-protein-related pathways. [11] [12] [13] [14] [15] [16] 47 Furthermore, recent evidence suggests that it may act as a negative regulator of Bcr-Abl, 48, 49 though the latter remains a matter of debate. 50 Its role in the nucleus is just beginning to be elucidated. Our present results suggest that p130
Bcr and p160 Bcr may be differentially distributed in the cytoplasmic vs nuclear compartments. Based on these data and the current literature, it may be worthwhile to explore the structural distinctions between these forms of Bcr, the biological interactions between Bcr and condensed chromatin, and a potential role for Bcr in cell cycle control and/or DNA repair mechanisms.
